An international study of improving treatment for the most severely ill with schizophrenia

Key information made simple

This study is looking at whether A double-blind, randomised controlled trial of risperidone compared to placebo augmentation will be carried out with 100 subjects can help people with Schizophrenia or Mental and Behavioural Disorders. Participants take part in A double-blind, randomised controlled trial of risperidone compared to placebo augmentation will be carried out with 100 subjects and complete follow-up assessments. Taking part may give some people access to A double-blind, randomised controlled trial of risperidone compared to placebo augmentation will be carried out with 100 subjects, but direct benefit is not guaranteed.

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.